Latest fiscal year 2025 · computed deterministically from XBRL 10-K data · coverage 100%
In fiscal 2025, Insight Molecular Diagnostics Inc. reported revenue of $4M, up 115.6% year over year. Operating margin was -1260.8% and net margin -1238.5%, on a free-cash-flow margin of -625.6% with capital expenditure at 78.5% of revenue. Every figure is computed directly from IMDX's SEC XBRL 10-K filing — deterministic, with no estimates.
| Fiscal year | Revenue | Op margin | Net margin |
|---|---|---|---|
| FY2025 | $4M | -1260.8% | -1238.5% |
| FY2024 | $2M | -3245.1% | -3225.0% |
| FY2023 | $2M | -1672.4% | -1848.4% |
| FY2022 | $1M | -1878.6% | -7609.8% |
| FY2021 | $2M | -2444.3% | -2916.2% |
How does IMDX compare against its actual peer set?
A CompsDesk subscription covers unlimited benchmark packs on any covered company: up to 19 metrics (6 core guaranteed) × up to 5 fiscal years × up to 12 chosen peers, percentile placement, the subject's figures cited to their SEC tag, form and period with every company identified by its CIK, PDF-ready HTML + CSV, generated on demand.
Related in the same sector: AAWH · ABBV · ABCL · ABT · ABUS · ACAD
Source: SEC EDGAR XBRL (10-K filings), latest filed values. "n/a" = not disclosed under mapped tags — never estimated. Informational benchmarking, not investment advice. © CompsDesk / Sam Arora.